Empagliflozin as an adjunctive therapy for type 1 diabetes
Abstract
Long-term complications of type 1 diabetes (T1D) due to exposure to chronic hyperglycaemia, including blindness, amputations, cardiovascular disease and kidney failure, remain a fear for many people living with T1D. Intensive insulin therapy reduces the risk of complications, but the majority of people with T1D fail to achieve recommended glycaemic targets (1-3). Furthermore, long-term intensive insulin therapy is associated with weight gain, a relevant side-effect as a significant proportion of people with T1D are now overweight (4).
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.